The Dow Jones Industrial Average ( ^DJI) fell 0.3%. The S&P 500 ( ^GSPC) rose more than 0.3%, and the tech-heavy Nasdaq Composite ( ^IXIC) popped 0.5% on the heels of two winning days in a row for the ...
In a report released yesterday, Mark Lipacis from Evercore ISI maintained a Hold rating on Qualcomm (QCOM – Research Report), with a price ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...
Hosted on MSN6h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Wall Street is drifting Thursday as gains for fashion brands and cigarette makers help offset drops for Ford Motor and ...
Stock market today: Wall Street drifts as Ford and Qualcomm offset rising fashion and tobacco stocks
Wall Street drifted to a mixed close as drops for Ford Motor and Qualcomm worked against buoyant fashion and cigarette stocks ...
Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback